Risk Factors of Venous Thromboembolic Disease in Cancer Patients Treated with Immune Checkpoint Inhibitor.

Julien Denis le Sève,Alexis F Guédon,Stéphanie Bordenave,Christian Agard,Jérôme Connault,Marc-Antoine Pistorius,Gaelle Quéreux,Olivier Espitia

Thrombosis and haemostasis（2023）

引用 1|浏览10

暂无评分

摘要

The prevalence of VTE was 14.2% under ICIs. IRAE and combine treatment of nivolumab and ipilimumab were associated with VTE. The pathophysiological mechanisms are multiple and complex with a possible link to aberrant activation of the immune system.

查看译文

关键词

cancer, pulmonary embolism, vein thrombosis, immune check point inhibitor, immune-related adverse event

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要